319 related articles for article (PubMed ID: 31103324)
1. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.
Li JY; Park HS; Huang GS; Young MR; Ratner E; Santin A; Damast S
Gynecol Oncol; 2021 Dec; 163(3):557-562. PubMed ID: 34602287
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type.
Ruiz I; Martín-Arruti M; Lopez-Lopez E; Garcia-Orad A
Gynecol Oncol; 2014 Jul; 134(1):20-3. PubMed ID: 24814467
[TBL] [Abstract][Full Text] [Related]
4. Does MMR status in endometrial cancer influence response to adjuvant therapy?
Kim SR; Pina A; Albert A; McAlpine J; Wolber R; Blake Gilks C; Kwon JS
Gynecol Oncol; 2018 Oct; 151(1):76-81. PubMed ID: 30172479
[TBL] [Abstract][Full Text] [Related]
5. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer.
Resnick KE; Frankel WL; Morrison CD; Fowler JM; Copeland LJ; Stephens J; Kim KH; Cohn DE
Gynecol Oncol; 2010 May; 117(2):234-8. PubMed ID: 20153885
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
9. Definitive radiotherapy for vaginal recurrence of early-stage endometrial cancer: survival outcomes and effect of mismatch repair status.
Alban G; Cheng T; Adleman J; Buzurovic I; Pretz J; Singer L; King M; Lee L
Int J Gynecol Cancer; 2021 Jul; 31(7):1007-1013. PubMed ID: 33858956
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
Loukovaara M; Pasanen A; Bützow R
Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.
Shih KK; Garg K; Levine DA; Kauff ND; Abu-Rustum NR; Soslow RA; Barakat RR
Gynecol Oncol; 2011 Oct; 123(1):88-94. PubMed ID: 21742371
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.
Backes FJ; Haag J; Cosgrove CM; Suarez A; Cohn DE; Goodfellow PJ
Cancer; 2019 Feb; 125(3):398-405. PubMed ID: 30561762
[TBL] [Abstract][Full Text] [Related]
14. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
[TBL] [Abstract][Full Text] [Related]
15. Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study.
Raffone A; Catena U; Travaglino A; Masciullo V; Spadola S; Della Corte L; Piermattei A; Insabato L; Zannoni GF; Scambia G; Zullo F; Bifulco G; Fanfani F; Di Spiezio Sardo A
Gynecol Oncol; 2021 Jun; 161(3):795-801. PubMed ID: 33812697
[TBL] [Abstract][Full Text] [Related]
16. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
17. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
18. Radiation therapy improves disease-specific survival in women with Stage II endometrioid endometrial cancer-Brachytherapy may be sufficient.
Nwachukwu CR; Von-Eyben R; Kidd EA
Brachytherapy; 2018; 17(2):383-391. PubMed ID: 29198879
[TBL] [Abstract][Full Text] [Related]
19. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
20. Overuse of external beam radiotherapy for stage I endometrial cancer.
Wright JD; Margolis B; Hou JY; Burke WM; Tergas AI; Huang Y; Hu JC; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2016 Jul; 215(1):75.e1-7. PubMed ID: 26875941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
